Loading quotes...

Forecast

The analysts' average price target is €91.61 (+1.68%). The median is €91.47 (+1.52%).

Buy	10
Hold	9
Sell	0

News Go to news feed

FDA approves Lantheus' TAUKLARIFY for tau-PET in Alzheimer

The U.S. FDA has approved TAUKLARIFY (florquinitau F 18) from Lantheus for positron emission tomography of the brain in adults to help assess Alzheimer-typical tau neurofibrillary tangles. The decision was based on two blinded studies with more than 500 subjects that showed high concordance in image readings; safety was evaluated in 1,734 subjects. Lantheus plans to support Alzheimer therapy programs through its Pharma Solutions business and is evaluating a path to broader commercial availability. » More on de.investing.com
Curium to buy Lantheus for up to $8bn in all-cash deal

CapVest-backed Curium will acquire Nasdaq-listed Lantheus for $102.50 per share in cash, plus non-transferable CVRs that could add up to $12.00 per share, bringing potential consideration to $114.50. The offer represents a roughly 38% premium to Lantheus' 60-day VWAP and has unanimous board approval. The combined group would operate across oncology, neurology and cardiology in more than 70 countries, integrating Curium's theranostics and manufacturing with Lantheus' US radiodiagnostics business. The transaction will be financed with debt and equity and is expected to close in the first half of 2027, subject to approvals. » More on finance.yahoo.com
Lantheus Holdings hits 52-week high at $111.52

Lantheus Holdings' stock rose to a 52-week high of $111.52 and is up roughly 39.7% year to date; market capitalization is about $7.25 billion. InvestingPro currently rates the stock as overvalued. The FDA issued a “Complete Response Letter” for the PET diagnostic kit LNTH-2501 due to manufacturing problems at a third‑party facility. Citizens and Mizuho have confirmed or raised price targets to $115 with positive assessments. Media reports say negotiations are underway over a possible sale to Curium, with an estimated offer of around $7 billion. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2023, Lantheus Hldg. has already paid €0.14 in dividends. The last payout was in December 2023.

Financials

In the last quarter, Lantheus Hldg. had revenue of €340.13M and net profit of €65.74M

(EUR)	June 2026	YoY
Revenue	340.13M	6.04%
Gross profit	211.92M	3.64%
Net profit	65.74M	1.61%
EBITDA	106.3M	2.14%

Fundamentals

Metric	Value
Market capitalization	€5.85B
Number of shares	65.3M
52-week high/low	€99.82 - €44.76
Dividends	No
Beta	-0.06
P/E ratio	23.86
PEG ratio	3.35
P/B ratio	4.99
P/S ratio	4.22

Company profile

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.

Name	Lantheus Hldg.
CEO	Mary Anne Heino
Headquarters	Bedford, ma USA
Website	lantheus.com
Sector	Health Care
Industry	Health Care Equipment & Supplies
IPO	08/28/2023
Employees	1,193